We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+1.77%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$6.85B
AUM Growth
+$217M
Cap. Flow
+$578M
Cap. Flow %
8.44%
Top 10 Hldgs %
38.32%
Holding
136
New
16
Increased
27
Reduced
15
Closed
11

Top Buys

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$112M
2
APLS
Apellis Pharmaceuticals
APLS
+$78.4M
3
PEN icon
Penumbra
PEN
+$62.3M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$54.4M
5
ARGX icon
argenx
ARGX
+$53.9M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$153M
2
INMD icon
InMode
INMD
+$19.9M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$17.3M
4
AGEN
Agenus
AGEN
+$12.9M
5
GH icon
Guardant Health
GH
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 93.33%
2 Financials 0.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$423M 6.17%
889,739
+16,484
+2% +$7.57M
RCKT icon
2
Rocket Pharmaceuticals
RCKT
$348M
$345M 5.04%
15,802,802
– –
ALNY icon
3
Alnylam Pharmaceuticals
ALNY
$36.3B
$335M 4.89%
1,975,879
+292,517
+17% +$54.4M
TMO icon
4
Thermo Fisher Scientific
TMO
$211B
$291M 4.24%
435,500
+19,500
+5% +$12.2M
MASI
5
DELISTED
Masimo
MASI
$249M 3.63%
849,971
+17,431
+2% +$4.96M
MRTX
6
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$229M 3.34%
1,561,497
+68,965
+5% +$10.7M
PTCT icon
7
PTC Therapeutics
PTCT
$6.37B
$211M 3.08%
5,293,966
– –
ILMN icon
8
Illumina
ILMN
$29.4B
$187M 2.72%
504,130
+7,821
+2% +$2.96M
PEN icon
9
Penumbra
PEN
$12.5B
$178M 2.6%
620,871
+235,677
+61% +$62.3M
VCEL icon
10
Vericel Corp
VCEL
$2.3B
$178M 2.59%
4,517,570
– –
TNDM icon
11
Tandem Diabetes Care
TNDM
$1.17B
$175M 2.55%
1,160,734
– –
NTRA icon
12
Natera
NTRA
$37.5B
$174M 2.54%
1,862,234
– –
ESTA icon
13
Establishment Labs
ESTA
$2.72B
$157M 2.29%
2,319,138
– –
CLDX icon
14
Celldex Therapeutics
CLDX
$2.77B
$152M 2.21%
3,921,579
+12,632
+0.3% +$550K
RXDX
15
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$129M 1.88%
3,264,031
– –
GMED icon
16
Globus Medical
GMED
$10.4B
$121M 1.76%
1,670,811
– –
CYTK icon
17
Cytokinetics
CYTK
$11B
$117M 1.7%
2,561,182
+561,182
+28% +$21.7M
RARE icon
18
Ultragenyx Pharmaceutical
RARE
$2.65B
$115M 1.69%
+1,373,284
New +$112M
RNAM
19
DELISTED
Avidity Biosciences
RNAM
$114M 1.66%
4,795,000
– –
ISEE
20
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$112M 1.64%
6,722,624
– –
ARGX icon
21
argenx
ARGX
$57.4B
$111M 1.62%
317,447
+177,136
+126% +$53.9M
ITOS
22
DELISTED
iTeos Therapeutics
ITOS
$110M 1.6%
2,353,015
– –
TXG icon
23
10x Genomics
TXG
$5.87B
$109M 1.6%
734,481
– –
AXNX
24
DELISTED
Axonics, Inc. Common Stock
AXNX
$109M 1.59%
1,943,864
– –
APLS
25
DELISTED
Apellis Pharmaceuticals
APLS
$94.1M 1.37%
+1,990,404
New +$78.4M
1
2 3 4 5

Similar funds

MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments's Q4 2021 Portfolio in Review

As of Q4 2021, RTW Investments held 136 positions worth $6.85B, up 3.3% from $6.63B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

RTW Investments deployed $578M of net new capital in Q4 2021, opening 16 new positions and adding to 27 existing holdings. Its largest new stake was Ultragenyx Pharmaceutical: 1,373,284 shares worth $115M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 91% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was IDEAYA Biosciences, an estimated $17.3M trimmed.

  • RTW Investments's largest Q4 2021 buy was Ultragenyx Pharmaceutical: 1,373,284 shares worth $115M.
  • RTW Investments added most to Penumbra in Q4 2021, an estimated $62.3M increase.
  • RTW Investments's biggest Q4 2021 reduction was IDEAYA Biosciences, cutting an estimated $17.3M.
  • RTW Investments fully exited Dicerna Pharmaceuticals, Inc. in Q4 2021, selling an estimated $153M.
  • RTW Investments's ten largest holdings make up 38% of its $6.85B portfolio in Q4 2021.
  • RTW Investments opened 16 new positions and closed 11 in Q4 2021.
  • RTW Investments's portfolio value rose 3.3% quarter-over-quarter to $6.85B.

Based on RTW Investments's 13F filing for Q4 2021, filed 14 Feb 2022.